Predictive value of abbreviated olfactory tests in prodromal Parkinson disease
- PMID: 37386033
- PMCID: PMC10310835
- DOI: 10.1038/s41531-023-00530-z
Predictive value of abbreviated olfactory tests in prodromal Parkinson disease
Abstract
There is disagreement in the literature whether olfaction may show specific impairments in Parkinson Disease (PD) and if olfactory tests comprised of selected odors could be more specific for diagnosis. We sought to validate previously proposed subsets of the University of Pennsylvania Smell Identification Test (UPSIT) odors for predicting conversion to PD in an independent, prodromal cohort. Conversion to PD was assessed in 229 participants in the Parkinson At Risk Study who completed baseline olfactory testing with the UPSIT and up to 12 years of clinical and imaging evaluations. No commercially available or proposed subset performed better than the full 40-item UPSIT. The proposed "PD-specific" subsets also did not perform better than expected by chance. We did not find evidence for selective olfactory impairment in Parkinson disease. Shorter odor identification tests, including commercially available 10-12 item tests, may have utility for ease of use and cost, but not for superior predictive value.
© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Conflict of interest statement
The authors declare no competing interests. P.A.V. has received grant funding from the Edmond J. Safra Foundation and Michael J. Fox Foundation and has been a consultant to Abbvie. J.F.M. has received grant support from the Department of Defense. D.J. is an employee of Denali Therapeutics, Inc. A.S. has been a consultant to the following companies: Biogen, Prilenia Therapeutics, Wave, Praxis Therapeutics, Alector, Merck and Prevail. He has received grant funding from the Michael J. Fox Foundation and NINDS. K.M. has been a consultant for Invicro, Sanofi, Biohaven, Takeda, Alkahest, Denali, Astellas, Bial, Pfizer, GE Healthcare, Lilly, Calico, Biomx, Neuramedy, Roche and the Michael J Fox Foundation.
Figures
References
Grants and funding
LinkOut - more resources
Full Text Sources
